Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 12;136(20):2245-2246.
doi: 10.1182/blood.2020008963.

COVID-19, plasma, and hypogammaglobulinemia

Michael F Murphy  1   2 , Sunny Dzik  3
Affiliations
Comment

COVID-19, plasma, and hypogammaglobulinemia

Michael F Murphy et al. Blood. .

Abstract

In this issue of Blood, Hueso et al report a study of COVID-19 convalescent plasma (CCP) in patients with COVID-19 and negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology with severe immunodeficiency due to prior treatment with anti-CD20 monoclonal antibodies. The study reports on the safety and efficacy of COVID-19 CCP in 17 patients with profound B-cell lymphopenia and protracted COVID-19 disease.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Coordinated immune response to SARS-CoV-2. Cellular immunity is central to the immune response to SARS-CoV-2. ACE2, angiotensin converting enzyme 2; KIR, killer cell immunoglobulin-like receptor; NK, natural killer; TCR, T-cell receptor; Treg, regulatory T cell. Figure courtesy of W. Garcia-Beltran.
See this image and copyright information in PMC

Comment on

  • Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, Camou F, Crickx E, Michel M, Mahevas M, Boutboul D, Azoulay E, Joseph A, Hermine O, Rouzaud C, Faguer S, Petua P, Pommeret F, Clerc S, Planquette B, Merabet F, London J, Zeller V, Ghez D, Veyer D, Ouedrani A, Gallian P, Pacanowski J, Mékinian A, Garnier M, Pirenne F, Tiberghien P, Lacombe K. Hueso T, et al. Blood. 2020 Nov 12;136(20):2290-2295. doi: 10.1182/blood.2020008423. Blood. 2020. PMID: 32959052 Free PMC article.

References

    1. Hueso T, Pouderoux C, Péré H, et al. . Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 disease. Blood. 2020;136(20):2290-2295. - PMC - PubMed
    1. Li L, Zhang W, Hu Y, et al. . Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial [published correction appears in JAMA. 2020;324(5):519]. JAMA. 2020;324(5):460-470. - PMC - PubMed
    1. Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. . Convalescent plasma for COVID-19. A randomized clinical trial [published online ahead of print 3 July 2020]. medRxiv. doi:10.1101/2020.07.01.20139857.
    1. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, et al. . Convalescent plasma for COVID-19: a multicenter, randomized clinical trial [published online ahead of print 1 September 2020]. medRxiv. doi:10.1101/2020.08.26.20182444.
    1. Joyner MJ, Senefeld JW, Klassen SA, et al. . Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience [published online ahead of print 12 August 2020]. medRxiv. doi:10.1101/2020.08.12.20169359.